⚔️ Head-to-head
Tirzepatide vs semaglutide
Pep lines up the two side by side — verdict, mechanism, and the dimensions that actually differ — so you can see where each one wins.
By MrPepTalks Editorial · Updated 2026-07-06
Tirzepatide
Mounjaro · Zepbound · LY3298176
promising🏆 Wins on head-to-head weight-loss data
semaglutide
unproven🏆 Wins on evidence grade
Tirzepatide
Dimension
semaglutide
Dual agonist — engages both the GIP and GLP-1 receptors, the two-lever design that is the whole reason it drew interest.
Drug class / mechanism
Single agonist — engages the GLP-1 receptor only, the original mechanism of the class and the one studied longest.
Blood-sugar control and body-weight reduction; sold as Mounjaro and Zepbound and studied across the SURMOUNT and SURPASS trial programs.
Commonly researched for
Blood-sugar control and body-weight reduction; sold as Ozempic, Wegovy and Rybelsus and studied across the SUSTAIN and STEP trial programs.
In the SURPASS-2 direct trial and in SURMOUNT program averages, the higher doses were associated with a larger average body-weight reduction (reported around one-fifth of body weight at the top dose).
🏆 winner
Head-to-head weight-loss data
In its own STEP program averages, semaglutide was associated with a smaller but still substantial average reduction (reported around the mid-teens percent of body weight).
Tier A — large phase-3 randomized controlled trials in humans, including a direct head-to-head against semaglutide.
Evidence grade
Tier A — an even deeper bench of large phase-3 trials plus a longer real-world record and a dedicated cardiovascular-outcomes trial.
🏆 winner
Sold as the branded prescription drugs Mounjaro and Zepbound, carrying on-label uses for type 2 diabetes and chronic weight management. Research-grade tirzepatide sold for lab use is not that product and is not FDA-approved.
Regulatory status
Sold as the branded prescription drugs Ozempic, Wegovy and Rybelsus, with on-label uses for type 2 diabetes and chronic weight management plus a cardiovascular on-label use for Wegovy. Research-grade semaglutide sold for lab use is not that product and is not FDA-approved.
🏆 winner
Gastrointestinal effects — nausea, diarrhea, constipation — are the most commonly reported, especially early on. The safety picture rests on the branded prescription product used under medical supervision.
Reported side-effect profile
The same gastrointestinal effects are the most commonly reported, with a longer post-market safety record behind it. Reported experiences vary by person and the branded product is used under medical supervision.
Widely sold as research-grade vials for laboratory use only; that material is not the FDA-approved branded product and carries gray-market purity and identity risk.
Availability of research-grade material
Also widely sold as research-grade vials for laboratory use only; likewise not the FDA-approved branded product and subject to the same sourcing hazards.
Tirzepatide data sheetThe terse reference: facts, forms, and Pep's verdict.
semaglutide data sheetThe terse reference: facts, forms, and Pep's verdict.
Send it to me →
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.